Month: December 2020

Company announcement nr. 49Fredericia, December 31st. 2020Waturu Holding A/S – Financial calendar 2021Financial calendar Waturu Holding A/S – 2021About Waturu Holding A/SFurther information:CEO Toke Reedtz, cell.: +45 5188 1262, e-mail: toke@waturu.comWaturu Holding A/SSjællandsgade 327100 VejleNasdaq First North Growth MarketFinancial reports:www.waturu.com/documentsFurther press related news:www.linkedin.com/company/waturu/www.facebook.com/WaturuDenmark/

Selskabsmeddelelse nr. 49Fredericia, den 31. december 2020Waturu Holding A/S – Finanskalender 2021Finanskalender Waturu Holding A/S – 2021Om Waturu Holding A/SWaturu Holding A/S er endvidere hovedaktionær i akvakultur teknologiselskabet Aquaturu A/S – der arbejder med teknologi der kan nedsætte bakterier, alger og parasitter i produktionsvand til landbaseret fiskeopdræt.

TORONTO, Dec. 31, 2020 (GLOBE NEWSWIRE) — Melior Resources Inc. (TSXV: “MLR”) (“Melior” or the “Company”) refers to its press release of September 24, 2020 regarding the Default Notice received from Pala Investments Ltd. (“Pala”) and the subsequent Standstill Agreement entered into with Pala.The Company announces that it has today entered into a further standstill amending agreement with Pala pursuant to which Pala has agreed to extend the standstill period until April 30, 2021.Furthermore, Melior has today also entered into an further amended demand promissory note (the “Amended Promissory Note”) with Pala extending the maturity of the loan from December 31, 2020 to April 30, 2021. All other terms of the Amended Promissory Note remain the same.MELIOR RESOURCES INC.Martyn ButtenshawInterim Chief Executive Officer+41 41 560 9070info@meliorresources.comNeither...

Company announcement – No. 64 / 2020Copenhagen, December 31, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutory Order on Issuers’ Disclosure Obligations, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. In Company announcement No. 60/2020 from December 11, 2020, Zealand announced an increase in share capital relating to the exercise of employee warrants. Following this announcement, the table below lists the total number of shares and voting rights in Zealand up to and including December 31, 2020.# # #About Zealand Pharma A/SZealand...

Dato:  31. december 2020Årets meddelelse nr.: 15Side 1 af 1BLUE VISION A/S – Finanskalender for 2021Hermed offentliggøres Blue Vision A/S’ finanskalender for 2021:30. marts 2021   Offentliggørelse af årsrapport for 202030. april 2021     Afholdelse af ordinær generalforsamling for 202030. august 2021  Offentliggørelse af delårsrapport 1. halvår 202130. marts 2022   Offentliggørelse af årsrapport for 202129. april 2022     Afholdelse af generalforsamling for 2021Med venlig hilsenBlue Vision A/SBestyrelsen

NEWTOWN, Pa., Dec. 31, 2020 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today a 1-for-35 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time today. Beginning on January 4, 2021, the Company’s common stock will trade on The Nasdaq Capital Market and the Toronto Stock Exchange on a split adjusted basis.Upon effectiveness, the reverse stock split will cause a reduction in the number of shares of common stock outstanding and issuable upon the conversion of the Company’s outstanding stock options and warrants in proportion to the ratio of the reverse split, and will cause a proportionate increase in the conversion and exercise prices of such stock options...

Niwot, Colorado., Dec. 31, 2020 (GLOBE NEWSWIRE) — Global Healthcare REIT, Inc. (Currently in a rebranding effort to Selectis Health, Inc.) (OTC: GBCS) (“Selectis” or the “Company”) is pleased to announce financial results for the third quarter ended September 30, 2020.THIRD QUARTER 2020 HIGHLIGHTSRecord revenue for the third quarter of $6,320,161 (2019 $1,989,103) a growth rate of 218% year-over -year and up 23% from the previous quarter;Net Income of $459,177 for the second quarter (2019 $176,582) a growth rate of 160% year-over -year;Earnings Per Share for the second quarter of $.02 per share basic and diluted;Net increase in Cash of $1,486,290 to a cash balance of $4,755,441 including restricted cash for the third quarter;Court approved operations transfer agreement to the Company’s wholly owned subsidiary...

Dato: 31. december 2020Årets meddelelse nr.: 14                                                           Ordinær generalforsamling – Blue Vision A/S, CVR-nr. 26 79 14 13 Den 31. december 2020 blev der afholdt ordinær generalforsamling i Blue Vision A/S med følgende dagsorden:1.   Præsentation af dirigent2.   Bestyrelsens beretning om selskabets virksomhed i det forløbne år3.   Fremlæggelse af revideret årsrapport til godkendelse og meddelelse af decharge for bestyrelse og direktion4.   Vedtagelse af fordeling af overskud eller underskud efter forslag fra bestyrelsen5.   Valg af bestyrelse6.   Valg af revisor7.   Eventuelle forslag fra aktionærer og bestyrelse      a. Beslutning om kapitalnedsættelse ved henlæggelse til en særlig reserve      b. Forslag til ændringer af selskabets vedtægter      c. Beslutning om godkendelse af betinget...